Stocktoria
Zymeworks Inc. ZYME
Zymeworks Inc. (ZYME) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $106.0M at a -76.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.596 |
| Retained earnings / assets | -2.751 |
| EBIT / assets | -0.267 |
| Equity / liabilities | 3.441 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ZYME | Zymeworks Inc. | 5/9 | -3.24 | — | +38.9% |
| ZVRA | ZEVRA THERAPEUTICS, INC. | 5/9 | -0.84 | 9 | +350.9% |
| TBPH | Theravance Biopharma, Inc. | 6/9 | 0.96 | 8.6 | +66.9% |
| URGN | UroGen Pharma Ltd. | 1/9 | -15.59 | — | +21.4% |
| GYRE | GYRE THERAPEUTICS, INC. | 3/9 | 4.52 | 71 | +10.2% |
| SIGA | SIGA TECHNOLOGIES INC | 5/9 | 16.02 | 12.1 | -31.8% |
| ASRT | Assertio Holdings, Inc. | 2/9 | -6.37 | — | -5% |
About Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
FAQ
Is ZYME financially healthy?
Zymeworks Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ZYME pay a dividend?
No, Zymeworks Inc. does not currently pay a dividend.
How profitable is ZYME?
In FY2025, Zymeworks Inc. had a net margin of -76.6% and a return on equity of -30.2%.
What is the analyst price target for ZYME?
The average Wall-Street price target for Zymeworks Inc. is $38.50, about 54.4% above the recent price, from 12 analysts (consensus: strong buy).
Is ZYME a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Zymeworks Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.